Notes
The study was funded by Bristol-Myers KK and Pfizer Japan Inc.
Reference
Kamae I, et al. Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clinical Therapeutics : 19 Nov 2015. Available from: URL: http://doi.org/10.1016/j.clinthera.2015.10.007
Rights and permissions
About this article
Cite this article
Apixaban cost effective for stroke prevention in NVAF in Japan. PharmacoEcon Outcomes News 743, 15 (2015). https://doi.org/10.1007/s40274-015-2680-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2680-y